InSilico Medicine jumps on progress in testing of new weight-loss drug

** Shares of InSilico Medicine Cayman TopCo 3696.HK jump 10.7% to HK$61.35, on course for biggest one-day pct rise since September 18

** Stock hits highest level in a week; second biggest pct gainer in Hang Seng Biotech Index .HSBIO, which rises 2.9%

** InSilico nominates ISM1354, a small molecule Glucose-dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist as pre-clinical candidate for potential intervention of obesity and related disorders, including type 2 diabetes with potential expanding into cardiovascular diseases

** Insilico has announced nomination of ten pre-clinical candidates in the first nine months of 2026 - co

** YTD, stock up 59.8%, while benchmark Hang Seng Index .HSI down 4.4%